Clinical trial
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With…
NCT00006265 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00006265 |
|---|---|
| Title | Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Official title | A Dose Escalation And Phase II Study Of Gemtuzumab Ozogamicin (CMA-676; Mylotarg) With High-Dose Cytarabine For Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | ara-C, gemtuzumab ozogamicin |
| Enrollment | 60 |
| Start date | Mar 1, 2001 |
| Primary completion | Dec 1, 2004 |
| Completion | May 1, 2005 |
| First posted | Sep 3, 2003 |
| Last update posted | Jul 14, 2016 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: